Midwest Professional Planners LTD. Boosts Stock Position in BioNTech SE (NASDAQ:BNTX)

Midwest Professional Planners LTD. increased its stake in BioNTech SE (NASDAQ:BNTX) by 7.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,177 shares of the company’s stock after buying an additional 212 shares during the period. Midwest Professional Planners LTD.’s holdings in BioNTech were worth $293,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC lifted its holdings in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the period. Frazier Financial Advisors LLC bought a new position in shares of BioNTech during the 4th quarter valued at $30,000. First Horizon Advisors Inc. bought a new position in shares of BioNTech during the 4th quarter valued at $38,000. Finally, UMB Bank n.a. bought a new position in shares of BioNTech during the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BioNTech stock traded down $0.91 during trading on Friday, reaching $85.46. 356,009 shares of the stock traded hands, compared to its average volume of 702,323. The company has a market capitalization of $20.32 billion, a price-to-earnings ratio of 172.74 and a beta of 0.23. The business has a fifty day simple moving average of $90.15 and a two-hundred day simple moving average of $92.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. BioNTech SE has a 52-week low of $78.02 and a 52-week high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Sell-side analysts expect that BioNTech SE will post -2 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BNTX shares. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. UBS Group lowered their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. JPMorgan Chase & Co. lowered their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. TD Cowen increased their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Finally, Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, BioNTech currently has a consensus rating of “Hold” and an average target price of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.